PIONYR IMMUNOTHERAPEUTICS


Associated tags: TREM1, Therapy, Immunosuppression, Gilead Sciences, TREM2, New Enterprise Associates, Tumor microenvironment, Pionýr, OrbiMed, Safety, Research, Pharmaceutical industry, Health, Immunotherapy, Myelocyte, Science, Oncology, Gilead, Cancer, Sofinnova, Tumor-associated macrophage, Vaccine

Locations: GILEAD

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Retrieved on: 
Monday, August 7, 2023
Gilead Sciences, Acquisition, Investment, CVR, Hippopotamus, New Enterprise Associates, IND, Security (finance), Pharmaceutical industry, Bank, Pionýr

BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible preferred stock priced at $7.15 per share.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.
  • “Ikena has made incredible strides this year, and we are glad to welcome the Pionyr shareholders to the Ikena team as we head into a pivotal time for our targeted oncology programs,” said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena.
  • The new Ikena shareholders include New Enterprise Associates, SV Health Investors, Sofinnova Investments, Vida Ventures, and Gilead Sciences.
  • “On behalf of our investors, board of directors, and the Pionyr executive team, I want to thank and congratulate the entire Pionyr team for their efforts.”
    Further details on the transaction are described below.

Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neutropenia, Immunotherapy, Therapy, Monoclonal antibody, Pharmacokinetics, Immunity, Head, Breast, Arthralgia, Trial of the century, Myelocyte, ASCO, Myalgia, American Society of Clinical Oncology, Patient, Stomatitis, Annual general meeting, Poster, CDT, R, Pembrolizumab, Tumor microenvironment, Society, Trauma trigger, TREM1, Safety, Fatigue, Medical imaging, Pharmaceutical industry

A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.

Key Points: 
  • A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.
  • The study will be featured in a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago and virtually.
  • The poster titled, “A Phase 1a Dose Escalation Study of PY159, a Monoclonal Antibody Targeting TREM1, Triggering Receptor Expressed on Myeloid Cells 1,” will be featured in a poster discussion session at the ASCO 2023 Annual Meeting at 3-4:30 pm CDT on June 3, 2023.
  • The abstract is currently available on the ASCO 2023 website, and the poster will be available on the Pionyr company website here after the completion of the ASCO poster session.

Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

Retrieved on: 
Thursday, March 23, 2023
Oncology, Health, Other Science, General Health, Clinical Trials, Research, Science, Immunotherapy, Myelocyte, Gilead Sciences, Therapy, Gilead, MARCO, TREM2, Pembrolizumab, Tumor microenvironment, TREM1, Safety, Pharmaceutical industry, Pionýr, IND

Pionyr Immunotherapeutics, Inc ., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements.

Key Points: 
  • Pionyr Immunotherapeutics, Inc ., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, today announced that Pionyr and Gilead Sciences, Inc. (Nasdaq: GILD) have mutually agreed to change their 2020 exclusive option agreements.
  • Gilead has waived its exclusive option to acquire Pionyr and certain other rights under the 2020 agreements.
  • In 2020, Gilead paid $275 million for its equity stake in Pionyr and agreed to fund Pionyr’s clinical and research activities in exchange for an exclusive option to acquire Pionyr for a pre-set price and contingent payments.
  • As part of this agreement, Gilead waives its exclusive option to acquire Pionyr.

Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Immunosuppression, Cytokine, Research, New Enterprise Associates, Therapy, Tumor microenvironment, Growth, Transcription activator-like effector nuclease, Cancer, MARCO, Sofinnova, Mouse, Neoplasm, TME, Poster, Chemokine, Phosphorylation, Immunotherapy, Tams, Myelocyte, Gilead, TREM2, ADCC, TREM1, Gilead Sciences, CPI, MDSC, Society, SITC, Society for Immunotherapy of Cancer, Program, Tumor-associated macrophage, Pharmaceutical industry, Vaccine, Pionýr

By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.

Key Points: 
  • By reprogramming myeloid cells, PY265 remodels the TME to unleash anti-tumor immunity and converts CPI-resistant tumors into treatment-responsive tumors.
  • The poster will be available on the Pionyr company website after the completion of the SITC poster session.
  • Pionyr has developed a therapeutic platform called Myeloid TuningTM, a process that rebalances the tumor microenvironment (TME) to promote anti-tumor immunity.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, PDAC, Safety, Immunosuppression, HNSCC, Sofinnova, Cytokine, Myelocyte, Immunotherapy, ADCC, NSCLC, Biomarker, Ovarian cancer, Colorectal cancer, Chemokine, Cancer, CRC, Pionýr, Patient, Tams, TREM2, Gilead, TREM1, Tumor-associated macrophage, TAM, Biology, Metastasis, Mab, TNBC, New Enterprise Associates, Head, Tumor microenvironment, Gilead Sciences, Research, Large-cell lung carcinoma, Pharmacokinetics, Myeloid tissue, Pembrolizumab, TME, Phosphorylation, Medical imaging, Pharmaceutical industry, Vaccine

In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.

Key Points: 
  • In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.
  • With these conclusions from Phase 1a, we are excited to begin this Phase 1b expansion study with leading clinical sites and investigators.
  • The multi-centered, US-based Phase 1a study evaluated the safety and tolerability of PY159 alone and in combination with pembrolizumab in multiple solid tumors and determined a recommended Phase 1b dose for expansion.
  • The Phase 1b study will evaluate PY159 administered alone and in combination with pembrolizumab in predefined tumor types.

Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit

Retrieved on: 
Thursday, June 16, 2022
Oncology, Health, Biometrics, General Health, Research, Science, Pharmaceutical, Sofinnova, Myelocyte, Therapy, Tumor-associated macrophage, Chief medical informatics officer, Tumor microenvironment, Immunosuppression, Immunotherapy, Cancer, ADCC, TME, Gilead, Metastasis, TREM1, New Enterprise Associates, Gilead Sciences, MARCO, TAM, TREM2, Pionýr, Tams, Vaccine, Pharmaceutical industry, Neoplasm

The presentation titled, Reprogramming TREM1+ Myeloid Cells to Overcome Immunotherapy Resistance in Solid Tumors, takes place at the 2nd Tumor Myeloid Directed Therapies Summit on June 16, 2022.

Key Points: 
  • The presentation titled, Reprogramming TREM1+ Myeloid Cells to Overcome Immunotherapy Resistance in Solid Tumors, takes place at the 2nd Tumor Myeloid Directed Therapies Summit on June 16, 2022.
  • PY159 is a humanized monoclonal antibody that specifically binds triggering receptor expressed on myeloid cells 1 (TREM1).
  • Pionyr has developed a therapeutic platform called Myeloid Tuning, a process that rebalances the tumor microenvironment (TME) to promote anti-tumor immunity.
  • Pionyr is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics after checkpoint inhibitors.

Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022

Retrieved on: 
Thursday, May 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Triple-negative breast cancer, TREM2, MTD, Myelocyte, Trae tha Truth, Immunotherapy, Neoplasm, Annual general meeting, HER2, TAM, Tams, Tumor microenvironment, Patient, Poster, Gilead, TME, Sofinnova, Macrophage, Pharmacokinetics, Society, Half-life, CD8, American Society of Clinical Oncology, Pembrolizumab, Metastasis, Index (publishing), Immunity, Adenocarcinoma, Safety, Monoclonal antibody, TREM1, ASCO, EVP, Large-cell lung carcinoma, Ovarian cancer, Oncology nursing, New Enterprise Associates, Colorectal cancer, Therapy, Tumor-associated macrophage, Renal cell carcinoma, Cancer, PK, Immunosuppression, Immunoglobulin G, ADCC, Gilead Sciences, Vaccine, Pharmaceutical industry, Medical imaging, Pionýr

The study will be featured in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7 virtually and in Chicago.

Key Points: 
  • The study will be featured in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7 virtually and in Chicago.
  • Pionyr developed PY314 to precisely bind human TREM2 and retune the tumor microenvironment by driving the selective depletion of TREM2 positive tumor-associated macrophages.
  • We have applied what we have learned from the Phase 1a study to identify a recommended dose for Phase 1b expansion studies.
  • The Phase 1a dose-escalation study of PY314 was a non-randomized, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PY314 as a single agent and in combination with checkpoint inhibitor pembrolizumab in 28 subjects with advanced solid tumors.

Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board

Retrieved on: 
Tuesday, May 3, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, TREM1, Department of Oncology, University of Cambridge, Department, University, Norwest Venture Partners, SVP, Tumor microenvironment, University of Lausanne, Ludwig Cancer Research, Immunity, Immunosuppression, TREM2, Associate, Metastasis, Macrophage, Immunotherapy, Inflammation, Cancer, Therapy, Computational biology, New Enterprise Associates, Institute, Genomics, Gilead Sciences, David Lipschultz, United States Air Force Scientific Advisory Board, Tumor-associated macrophage, Yale Physician Associate Program, Janssen, B cell, Bristol Myers Squibb, Precision medicine, New England Institute of Religious Research, Myelocyte, Sofinnova, Myeloid tissue, Vaccine, Pharmaceutical industry, Pionýr

As a pioneer and leader in harnessing the power of myeloid cells in the tumor microenvironment to fight cancer, Pionyr is committed to scientific excellence and advancement of the field, as exemplified by our scientific advisory board, said Steven P. James, President and Chief Executive Officer at Pionyr.

Key Points: 
  • As a pioneer and leader in harnessing the power of myeloid cells in the tumor microenvironment to fight cancer, Pionyr is committed to scientific excellence and advancement of the field, as exemplified by our scientific advisory board, said Steven P. James, President and Chief Executive Officer at Pionyr.
  • We are proud to welcome these experts in immuno-oncology, myeloid, and computational biology to our scientific advisory board.
  • Dr. Joyce is a Professor in the Department of Oncology at the University of Lausanne, Switzerland, and a Full Member of the international Ludwig Institute for Cancer Research.
  • Pionyr has paved new territory in modulating myeloid cell biology as a novel modality for cancer R&D, said Kevin P. Baker, Ph.D., SVP and Chief Development Officer at Pionyr and Scientific Advisory Board Chair.